Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer
NCT05373628 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2022-05-13
Summary
Patients with breast masses and suspected breast malignancies by ultrasound / mammography were prospectively included. After routine MRI scanning, all patients underwent average cell size imaging sequence scanning, and finally underwent breast MRI enhanced scanning. Inclusion criteria of breast cancer patients: (1) breast cancer confirmed by surgery or biopsy; (2) The status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER-2), Ki-67 and lymphatic vessel invasion (LVI) in breast cancer were clearly diagnosed by pathology; (3) Routine MRI, PGSE and OGSE scans were performed within 1 week before pathological examination. Exclusion criteria: (1) breast tumor patients who had received treatment before PGSE and OGSE sequence scanning; (2) Patients who underwent breast tumor puncture within 2 weeks before PGSE and OGSE sequence scanning; (3) Patients with breast masses without surgery or biopsy after PGSE and OGSE sequence scanning; (4) The breast mass was confirmed to be other diseases except breast cancer by pathological examination; (5) Due to poor image quality caused by motion artifacts or other reasons, PGSE and OGSE sequence post-processing cannot be carried out. All subjects were required to sign written informed consent.
Breast MRI data were collected using Philips ingenia DNA 3T MR scanner in the Netherlands. All subjects used standardized breast MRI scanning schemes, including T2 weighted imaging (T2WI), T1 weighted imaging (T1WI), diffusion weighted imaging (DWI), PGSE, OGSE and contrast dynamic enhancement (DCE). Three quantitative parameters of VIN, DEX and D were derived from MATLAB software. The correlation between the quantitative parameters of mean cell size imaging and pathological indexes Er, PR, HER-2, Ki-67 and LVI was evaluated by Spearman correlation analysis. The predictive factors of the quantitative parameters of mean cell size model for different pathological characteristics of breast cancer were determined by logistic regression model, The diagnostic efficacy of quantitative parameters of mean cell size model for pathological classification indexes was evaluated by subject operating characteristic (ROC) curve and area under curve (AUC).
Conditions
- Breast Carcinoma; Magnetic Resonance Imaging;OGSE
Interventions
- DIAGNOSTIC_TEST
-
Gradient and pulse imaging
A novel diffusion-based magnetic resonance imaging method
Sponsors & Collaborators
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
lead OTHER
Principal Investigators
-
Zhang Xiang, M.D · Sun Yat-sen University
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-11
- Primary Completion
- 2023-06-01
- Completion
- 2023-07-01
Countries
- China
Study Locations
More Related Trials
-
Breast Masses MRI Volumetry Compared to Post-operative Pathological Volume
NCT07268300 ·Status: NOT_YET_RECRUITING
-
Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy
NCT05301790 ·Status: UNKNOWN
-
Application of Radiomics in Breast Cancer
NCT04483804 ·Status: RECRUITING
-
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
NCT06102018 ·Status: RECRUITING
-
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
NCT04535466 ·Status: UNKNOWN
-
The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer
NCT03861221 ·Status: COMPLETED ·Phase: NA
-
Comparison of Ultrasound and Breast MRI for Breast Cancer Detection
NCT05797545 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis
NCT04429269 ·Status: UNKNOWN
-
PET/MR Radiomics for Breast Cancer Diagnosis
NCT05466760 ·Status: UNKNOWN
-
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
NCT03080623 ·Status: COMPLETED
-
Prospective Ultrafast MRI Radiomics for Breast Cancer
NCT06104189 ·Status: COMPLETED
-
Ultrasound and Mammography for Screening Breast Cancer in Chinese Women
NCT01880853 ·Status: COMPLETED ·Phase: NA
-
MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
NCT04004559 ·Status: UNKNOWN
-
Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast Cancer
NCT06546072 ·Status: COMPLETED
-
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients
NCT02742168 ·Status: COMPLETED ·Phase: NA
-
Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China
NCT04076111 ·Status: NOT_YET_RECRUITING
-
MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Therapy in Breast Cancer
NCT04909554 ·Status: COMPLETED
-
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer
NCT05243121 ·Status: UNKNOWN
-
Prospective Radiomics Study for Breast Cancer
NCT06095414 ·Status: COMPLETED
-
Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer
NCT03851497 ·Status: COMPLETED
-
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT01805076 ·Status: COMPLETED ·Phase: PHASE3
-
Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy
NCT02556684 ·Status: UNKNOWN
-
Detection and Analysis of MBC With Heterogeneous ER Expression
NCT05392985 ·Status: COMPLETED
-
Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
NCT00291304 ·Status: TERMINATED ·Phase: PHASE2
-
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
NCT04683770 ·Status: UNKNOWN